Bimagrumab
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About Bimagrumab
Bimagrumab is a human monoclonal antibody that blocks activin type II receptors (ActRII), inhibiting myostatin and related ligands to simultaneously increase muscle mass and reduce fat mass — a unique dual body composition effect. In a Phase II trial of diabetic patients, bimagrumab reduced fat mass by 20.5% and increased lean mass by 3.6% over 48 weeks. It is being studied in combination with semaglutide to preserve muscle during GLP-1-driven weight loss.
Science
Mechanism of Action
Binds and blocks activin type IIA and IIB receptors, preventing myostatin and activin signaling that normally suppresses muscle growth; simultaneously promotes adipose tissue browning and fat oxidation through ActRII-dependent pathways.
Dosing
Typical Protocol
10 mg/kg IV infusion every 4 weeks in clinical trials; subcutaneous formulation under development.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
Bimagrumab is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.